ArticleArthritis care & research2026
Rheumatologic Manifestations of Patients With Type B Insulin Resistance.
Article in Arthritis care & research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
objectiveThe objectives of this study were to identify laboratory and clinical features associated with type B insulin resistance (TBIR), a rare condition caused by autoantibodies that inhibit the insulin receptor, most frequently occurring in the setting of systemic lupus erythematosus (SLE), and to increase awareness of this rare, life-threatening condition.
methodsThirty-eight patients with TBIR who were seen at the National Institutes of Health between 1976 and 2024 were included. Retrospective chart review was performed to assign primary rheumatologic diagnoses, characterize endocrinologic laboratory measurements, and identify clinical and laboratory manifestations of SLE, including hypocomplementemia, cytopenias, and autoantibody seropositivity.
resultsSLE was the most frequent underlying diagnosis (81.5%); one patient each had Sjögren disease and primary biliary cholangitis. Patients were predominantly female (89.5%) and Black/African American (84.2%). The median Systemic Lupus Erythematosus Disease Activity Index 2000 score was 14 (interquartile range 7). High or very high U1 RNP autoantibodies were seen in >50% of patients. TBIR was associated with a high prevalence of acute neuropathies of the seventh and/or eighth cranial nerve (18.4%), angioedema (10.5%), and uveitis (5%).
conclusionTBIR can be a rare complication of SLE, is associated with the presence of high-titer U1 RNP autoantibodies, and may co-occur with other rare SLE manifestations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.